creat bluematrix
celg transact close
messag late last week neutral announc
us feder trade commiss ftc accept consent order celg
transact regulatori requir satisfi close celg acquisit
yesterday otezla divestitur promptli follow celg
notes/exchang offer amount new note issu
expir yesterday et settlement date follow remain
neutral rate
financi bmy-celg powerhous profit least
compani reduc cost work toward key pipelin mileston view
earli deal-clos increment posit combin compani broadli
line compani expect close occur prior recent meet
manag reiterate could deliv least one-third project
target annual cost synergi despit otezla sale chang
expect annual synergi tradabl conting valu
right cvr structur pay celg sharehold cash one time fda approv
secur three product ozanimod
end expect cvr share trade lockstep
probabl regulatori success three asset manag
state plan buy back cvr share cvr earli
celg enter catalyst rich view biggest swing
factor ozanimod ulcer coliti final data
result addit three asset tie cvr
potenti catalyst event ozanimod pdufa date
expect fda approv liso-cel sometim
addit asset recent approv reblozyl luspatercept beta thalassemia-
relat anemia inreb fedratinib myelofibrosi upcom confer
decemb expect pivot data liso-cel transcend nhl studi first
look bispecif anti-bcma product ask abstract
see note colleagu michael schmidt abstract highlight
manag sanguin process deliv success despit
seemingli higher failur rate drug administr vs similar data impli
buy yescarta look beyond expect releas full result
studi opdivo low-dos yervoy chemotherapi cycl
nsclc see note explain lung cancer opportun i/o combin
expect data like present april addit
expect top-lin result opdivo cabometyx rcc kidney
neoadjuv studi lung cancer
share past month lead transact close
organ structur respect leadership team chang share
june leadership personnel chang take effect day post-clos
commerci team split hematolog three global franchis
oncolog immunolog cardiovascular hematolog key area compani
near-term success along four potenti near-term launch busi group
dr chri boerner continu role execut vice presid chief
commerci offic overse combin compani
oncolog immunolog cardiovascular global busi world-wide valu
access price world-wide commerci oper global medic
nadim ahm serv presid hematolog previous
presid global hematolog oncolog celgen
page analyst certif import disclosur
met manag week ago dr boerner highlight benefit
separ commerci sale team accordingli allow organ effici
well headcount reduct see note highlight meet w/
 team split earli research earli develop ed later-
line would includ phase trial global drug develop
dr rupert vessey serv presid research earli develop
group immedi past presid research earli develop
celgen
dr samit hirawat join chief medic offic global
drug develop previous execut vice presid head
oncolog develop novn-swx
financ organ continu oper cours requir transit
standard process remit organ includ busi insight analyt
procur
david elkin serv execut vice presid chief offic
cfo previous cfo celgen
charl bancroft continu serv execut lead integr
retir year servic compani previous chief
financi offic cfo head global busi oper
work close david elkin ensur transit financi oper
dr giovanni caforio continu serv chairman board chief execut
offic ceo combin compani
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic bristol-my
squibb compani celgen corpor next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori bristol-my squibb compani
rate price target histori celgen corpor celg
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
creat bluematrix
page analyst certif import disclosur
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
